MORE than 2.8 million courses of Pfizer Inc’s PFE.N COVID-19 oral antiviral treatment Paxlovid have been made available at pharmacies around the United States, with the Biden administration working to improve access to the drug.
As Paxlovid has become more widely used, some patients have reported that COVID-19 symptoms recurred after completing treatment and experiencing improvement.
Here is the latest information on these rebounds:
How common is a recurrence of COVID symptoms shortly after Paxlovid treatment?
Dozens of individuals have reported rebounding COVID symptoms on social media or to the U.S. Food and Drug Administration after taking Paxlovid, but Pfizer suggests the experience is rare.
Pfizer has said that from more than 300,000 patients it is monitoring who received the 5-day treatment, around 1-in-3,000 - about 0.03% - reported a relapse after taking the pills.
That is a lower rate than Pfizer saw in its Paxlovid clinical trial, where about 2% of participants experienced a rebound in viral levels after completing treatment.
The Pfizer trial suggested relapses may be a broader COVID trend as a similar number of those who had received a placebo also had a rebound in viral load levels.
Why are these recurrences happening?
The cause not yet known. Some doctors have suggested that because the drug attacks the virus so quickly, some patients' immune responses to COVID may be muted, allowing the virus to replicate again. Others have said there may be a not yet identified common characteristic among those who suffer a rebound.
Pfizer Chief Development Officer William Pao said it may be related to the virus itself, not Paxlovid, since the phenomenon was found among patients who got the drug and those who did not.
The U.S. Food and Drug Administration has also said it is unclear whether rebounds are related to Paxlovid.
Should I take a second course of Paxlovid after a rebound?
Not according to the FDA. It said last week that there is no evidence of benefit for taking a second 5-day course of the pills or for a 10-day course.
Pfizer has suggested otherwise. Chief Executive Albert Bourla has said that patients and doctors had told Pfizer a second five-day course of Paxlovid had cleared the virus. Mikael Dolsten, the company’s chief scientific officer, recently said some immunocompromised patients “may carry this virus for a very, very long time,” and may need to take multiple courses or for an extended duration.
The FDA stressed that the rebounds do not change Paxlovid's ability to reduce hospitalization and death.
Who is eligible for Paxlovid?
Eligibility for Paxlovid differs by country. In the United States, Paxlovid is authorized for patients at high risk for progression to severe COVID-19 whether or not they are vaccinated.
According the U.S. Centers for Disease Control and Prevention, these groups include anyone aged 65 or older and people with risk factors such as obesity, diabetes, cancer or use of immunosuppressive medicine. Bourla has estimated half of American adults are eligible.
Does Paxlovid work against long COVID?
Paxlovid is not authorized to treat the lingering, debilitating condition known as long COVID. However there have been recent case studies of patients with long COVID who experienced relief of symptoms after taking Paxlovid. Read full story
Reuters
Thu May 12 2022
![EXPLAINER - Some patients reporting COVID rebounds after taking Pfizer pills EXPLAINER - Some patients reporting COVID rebounds after taking Pfizer pills](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-05/41652313241_Paxlovid.jpg)
More than 2.8 million courses of Pfizer Incs PFE.N COVID-19 oral antiviral treatment Paxlovid have been made available at pharmacies around the United States. - REUTERS
![Usaha pujuk Pan-gon tidak berhasil - Yusoff Mahadi Usaha pujuk Pan-gon tidak berhasil - Yusoff Mahadi](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-07/81721124841_TBFAM.jpg)
Usaha pujuk Pan-gon tidak berhasil - Yusoff Mahadi
FAM pernah berusaha memujuk Kim Pan-gon untuk terus mengemudi skuad Harimau Malaya hingga kontraknya tamat secara rasmi pada akhir tahun depan.
![Kaspersky tinggalkan pasaran AS bermula 20 Julai ini Kaspersky tinggalkan pasaran AS bermula 20 Julai ini](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-02/51708604164_kasperskyancamans.jpg)
Kaspersky tinggalkan pasaran AS bermula 20 Julai ini
Kaspersky mengesahkan kurang 50 pekerja akan terkesan, dan mereka akan diberikan pampasan susulan penutupan syarikat tersebut.
![Sultan Selangor jalani pemeriksaan kesihatan untuk pembedahan katarak mata Sultan Selangor jalani pemeriksaan kesihatan untuk pembedahan katarak mata](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-07/81721125507_SultanSelangor.jpg)
Sultan Selangor jalani pemeriksaan kesihatan untuk pembedahan katarak mata
Sultan Selangor Sultan kini berada di hospital untuk rawatan pemeriksaan kesihatan bagi menjalani prosedur pembedahan katarak mata.
Enam MP kekal : Tak adil salahkan Speaker - Gobind
Mengenai keputusan mengekalkan enam kerusi Parlimen bekas ahli Bersatu, Gobind Singh Deo berkata tidak adil untuk salahkan Speaker buat keputusan yang diperuntukkan undang-undang.
![Tokan dadah ditahan bersama dua pucuk pistol di Alor Setar Tokan dadah ditahan bersama dua pucuk pistol di Alor Setar](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-07/51721123744_tokandadah.jpg)
Tokan dadah ditahan bersama dua pucuk pistol di Alor Setar
Polis menahan dua lelaki dan merampas dua pucuk pistol serta pelbagai jenis dadah dalam dua tangkapan di Taman Lam Foong, di Alor Setar.
![Tiada tempat selamat di Gaza, kata ketua PBB Tiada tempat selamat di Gaza, kata ketua PBB](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-06/51719354914_Destroyedbuildings.jpg)
Tiada tempat selamat di Gaza, kata ketua PBB
Beliau berkata tahap pertempuran dan kemusnahan yang melampau di Gaza tidak dapat difahami dan tidak boleh dimaafkan.
![Saya tidak fitnah Lim Guan Eng, cuma jelas tentang siasatan SPRM - Muhyiddin Saya tidak fitnah Lim Guan Eng, cuma jelas tentang siasatan SPRM - Muhyiddin](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-07/51721121786_MuhyiddinYassin.jpg)
Saya tidak fitnah Lim Guan Eng, cuma jelas tentang siasatan SPRM - Muhyiddin
Muhyiddin memberitahu bahawa beliau tidak memfitnah Lim Guan Eng berhubung isu pengecualian cukai terhadap Yayasan Albukhary.
![Saintis kesan gen bantu rawat kanser pankreas Saintis kesan gen bantu rawat kanser pankreas](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-04/81712376317_TujuanForensik.jpg)
Saintis kesan gen bantu rawat kanser pankreas
Gen HNF4A (Hepatocyte Nuclear Factor 4 Alpha) didapati akan berhenti berfungsi pada tubuh pesakit kanser pankreas.
Pantau Agenda Reformasi: Potensi dan cabaran percambahan e-Sukan di Malaysia
Pengerusi Gabungan Pelajar Melayu Semenanjung (GPMS) Negeri Selangor
merangkap Timbalan Presiden Majlis Belia Negeri Selangor
E-Sukan mampu mencetak nama Malaysia di pentas dunia. Memahami potensi, kekangan dan peranan yang perlu dimainkan semua pihak dalam melahirkan lebih ramai pemain E-Sukan yang berjaya, seterusnya menyokong pembangunan industri E-Sukan negara.
SRG cipta sejarah pasukan Malaysia pertama juarai MSC MLBB 2024
merangkap Timbalan Presiden Majlis Belia Negeri Selangor
E-Sukan mampu mencetak nama Malaysia di pentas dunia. Memahami potensi, kekangan dan peranan yang perlu dimainkan semua pihak dalam melahirkan lebih ramai pemain E-Sukan yang berjaya, seterusnya menyokong pembangunan industri E-Sukan negara.
SRG cipta sejarah pasukan Malaysia pertama juarai MSC MLBB 2024
Jualan kereta di Malaysia diunjur cecah 765,000 unit
Persatuan Automotif Malaysia (MAA) melakukan semakan semula berkaitan sasaran jumlah keseluruhan industri (TIV) kepada 765,000 unit berbanding unjuran awal 740,000 unit untuk 2024. Semakan dibuat disokong oleh persekitaran ekonomi yang positif dan jumlah tempatan tertunggak yang masih berada pada tahap yang baik
![Ubat Paxlovid masih berkesan rawat COVID-19 Ubat Paxlovid masih berkesan rawat COVID-19](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2023-10/61696481353_MuhammadRadzi.jpg)
Ubat Paxlovid masih berkesan rawat COVID-19
Rawatan antiviral itu boleh mengurangkan gejala COVID-19 dan mengelakkan penyakit daripada menjadi lebih teruk.
![Vaksinasi, ubat antiviral strategi tangani gelombang baharu COVID-19 - Khairy Vaksinasi, ubat antiviral strategi tangani gelombang baharu COVID-19 - Khairy](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-06/41654690954_KhairyJamaludin.jpg)
Vaksinasi, ubat antiviral strategi tangani gelombang baharu COVID-19 - Khairy
Masih terdapat lebih 30 peratus golongan dewasa di negara ini yang belum mendapatkan dos penggalak setakat 7 Julai.
![Pfizer dakwa pil COVID-19 keluarannya mampu kurangkan kemasukan ke hospital Pfizer dakwa pil COVID-19 keluarannya mampu kurangkan kemasukan ke hospital](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-11/51636156278_Paxlovid.jpg)
Pfizer dakwa pil COVID-19 keluarannya mampu kurangkan kemasukan ke hospital
Pfizer menamatkan ujian klinikal ke atas Paxlovid, susulan keputusan awal yang sangat positif.